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Objectives: The influence of prosthesis–patient mismatch on outcome after aortic valve replacement is contro-
versial. This study analyzed the impact of prosthesis–patient mismatch on survival, the extent of left ventricular
mass, and physical capacity after replacement with a small-size prosthesis.
Patients and Methods: A total of 157 patients who underwent valve replacement for pure aortic stenosis were
reviewed. Late mortality, morbidity, left ventricular mass regression, transprosthetic gradient at rest and after
exercise, exercise capacity, and occurrence of arrhythmias were evaluated.
Results: Prosthesis–patient mismatch, defined as an indexed effective orifice area of 0.75 cm2/m2 or more, oc-
curred in 96 (61.1%) patients and had no significant impact on early and late mortality. The only independent
predictor of mortality was age greater than 65 years. At follow-up, multivariate analysis of prosthetic gradient
at rest of 35 mm Hg end exercise capacity or more revealed that both these evidences were associated with
high left ventricular mass (P< .001), female gender (P< .001), and follow-up time (P< .001). Arrhythmias
occurred during exercise in 34.1% of patients (40/117). Multivariate analysis of occurrence of arrhythmias
revealed that they were associated with high mean transprosthetic gradients: values of 50 mm Hg or more during
exercise had 95% sensitivity and 72% specificity for predicting arrhythmias.
Conclusion: Prosthesis–patient mismatch failed to demonstrate any significant impact on early and late mortality
and morbidity and in left ventricular mass regression. High transprosthetic gradients influence exercise capacity
and occurrence of arrhythmias.Aortic valve replacement (AVR) is the treatment of choice
for patients with severe aortic stenosis (AS). Despite an
increasing number of high-risk patients, mortality and
morbidity of surgical treatment remain low. Complete relief
of transvalvular gradient is the goal of surgery. Often, a pros-
thesis is implanted that is too small for the patient’s need.
Prosthesis–patient mismatch (PPM), as first described by
Rahimtoola1 in 1978, occurs when the effective orifice area
(EOA) of the prosthesis is too small in relation to patient
body size and thus can result in persistent left ventricular
(LV) outflow tract obstruction. The impact of PPM on hemo-
dynamic status, patient survival, and morbidity has recently
been questioned.2-4 Several reports, involving a large number
of patients, concluded that PPM can be observed in 19% to
70% of patients undergoing AVR5,6 and that the valve size
may have no effect on early and late clinical results.7-10 The
aim of this study was to evaluate PPM occurrence in patients
who underwent AVR for pure AS with size 19- or 21-mm
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transprosthetic gradients, exercise capacity, and arrhythmia
occurrence with regard to late mortality and morbidity.
MATERIAL AND METHODS
Definition of PPM
PPM occurs when the size of an artificial valve is inadequate for the
recipient.1,11 As previously reported, PPM can be predicted by calculating
the projected indexed EOA (EOAi)4,12,13 derived from the published normal
values of EOA for each model and size of prosthesis2,6,12,14-17 divided by
body surface area (BSA). PPM was previously defined as not clinically
significant (ie, mild or no PPM) if EOA was greater than 0.85 cm/m2, as
moderate if was greater than 0.65 cm/m2 and 0.85 cm/m2 or less, and severe
if was 0.65 cm2/m2 or less.6,18 In this present study, we defined PPM as
EOAi of 0.75 cm2/m2 or less. The selection of this value was based primarily
on results of previous studies.2,19 In addition, we did a preliminary analysis
that confirmed that this cutoff value provides the best compromise between
sensitivity and specificity in the aim of this study end point.2,18,19
Study Population
This retrospective studywas conducted at a single cardiac surgery center.
The group comprised 157 patients who underwent isolated AVR for pure
AS between January 1997 and December 2002. Sixty-nine (43.9 %)
received a 19-mm prosthesis and 88 (56.1%) a 21-mm prosthesis. Mean
age was 66.7  8.7 years. A bioprosthesis was implanted in 73 (46.5%)
patients and a mechanical valve in 84 (53.5%). The choice was based on
the patient’s age, history of thomboembolism or bleeding disorders, liver
disease, and preference of the patient or cardiologist. Coronary angiograms
were evaluated in all patients before surgery. To obtain a study population as
homogeneous as possible and to avoid any confounding interference onrgery c September 2009
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AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BSA ¼ body surface area
CI ¼ confidence intervals
EOA ¼ effective orifice area
EOAi ¼ indexed effective orifice area
ILVM ¼ indexed left ventricular mass
LV ¼ left ventricular
LVM ¼ left ventricular mass
MPG ¼ mean prosthetic gradient
OR ¼ odds ratio
PEC ¼ predicted maximum exercise capacity
PPM ¼ prosthesis–patient mismatch
results, we used the following exclusion criteria: previous cardiac surgery,
associated aortic diseases, simultaneous mitral or tricuspid replacement or
repair, previous myocardial infarction, evidence of coronary lesions, poor
cardiac function as indicated by ejection fraction less than 40%, and chronic
atrial fibrillation. The cutoff point was 75 years for aged patients. Preoper-
ative and surgical variables are summarized in Table 1.
All patients had echocardiographic evaluation before surgery by an ex-
perienced echocardiographer and were followed up with serial transthoracic
evaluations before discharge, 3 to 6 months after the operation, and annually
thereafter. LV function was evaluated by the ejection fraction calculated by
the Simpson rule. The LVM was assessed by the following formula: LVM
¼ 1.04 ([LVIDdþIVSDþLPWDd] 3[LVIDd] 3)13.6, and was normal-
ized to BSA. (LVIDd¼ LV internal diameter in diastole; IVSD¼ intraven-
tricular septal diameter; LPWDd ¼ left posterior wall diameter in diastole.)
LV hypertrophy was defined as an indexed LVmass (ILVM) more than 130
g/m2 in men and more than 100 g/m2 in women.20 The peak and mean pros-
thetic gradients (MPGs) were calculated from continuous-wave Doppler
measurements using the modified Bernoulli equation. The measurements
were made according to the recommendations of the American Society of
Echography.21
Follow-up ranged from 58 to 129months (mean 83.8 31.9). Sixty-four
percent (82/128) of patients had a follow-up of more than 7 years. Scheduled
follow-up consisted in clinical interview and electrocardiographic and echo-
cardiographic evaluation at rest and after exercise.
Stress test was performed in all patients 5 days after therapy withdrawal.
The bicycle exercise test was conducted according to a standard protocol
starting from a workload of 25 W and increased by 25 W at 2-minute inter-
vals. Data on atrial and ventricular arrhythmias were recorded during each
stage of exercise and during the recovery period. The reference workload for
healthy individuals was 2.5 W/kg in women and 3.0 W/kg in men between
21 and 30 years, minus 10% for each decade. This target exercise was cal-
culated for each patient. The achievedmaximumworkload was registered as
percentage of age, sex, weight-predictedmaximum exercise capacity (PEC).
Tests were limited by symptoms, blood pressure higher than 200/100 mm
Hg, arrhythmias, and exhaustion or achievement of 100% of age, sex,
and weight PEC. The recording of Doppler signals was started after 90 sec-
onds, with the patients exercising in the supine position. Arrhythmias were
assessed as reported by the American College of Cardiology/American
Heart Association.22 For this present study, only ventricular arrhythmias
were considered and were classified as reported by Frolkis and associates23
(frequent ventricular ectopic beats of 10% or less of QRS complexes during
30 seconds, bigeminy/trigeminy, couplets, sustained or unsustained ventric-
ular tachycardia during exercise or recovery). These criteria were defined
in the study protocol and coded by the physician who conducted theThe Journal of Thoracic and Cexamination. Five patients had pre-existing atrial fibrillation and were
excluded from arrhythmias analysis.
Morbidity and mortality were specified according to the Society of
Thoracic Surgeons/American Association for Thoracic Surgery guidelines
for reporting events after cardiac valve operations.24 According to these,
we considered valve-related mortality and morbidity as deaths caused by
structural valve deterioration, nonstructural deterioration, valve thrombosis,
embolism, or bleeding. Operative mortality was defined as death within
30 days after operation. All patients who were reoperated on for any cause
were excluded from final follow-up.
The hospital ethics committee approved this study, and individual
informed consent was obtained from each patient included in the study.
Surgical Technique
All surgical procedures were performed by the same surgeon. The surgical
approach consisted in median sternotomy, hollow-fiber oxygenators, and
roller pumps. In all cases, the ascending aorta and right atrium were cannu-
lated. Pumpflowwas kept at about 2.5 L $min1 $m2 and the arterial pressure
at about 70 mm Hg. The myocardium was protected by intermittent antero-
grade cold blood cardioplegic solution infused into the ascending aorta. Ret-
rograde cardioplegia was never used. Lowest core temperature varied from
33C to 36C. The valves were excised through an oblique aortotomy and
the prostheses were implanted with 2–0 polyester mattress suture. Reinforce-
ment with Teflon pledgets was not routinely used but was necessary in
11 patients. Mean aortic crossclamping time was 67.8 22.4 minutes.
End Points
Late result of AVR with 19- or 21-mm prostheses was the first end point
of this study. Secondary end points were as follows: (1) incidence of PPM
TABLE 1. Preoperative and surgical variables
Variable
EOA/BSA
 0.75 cm2/m2
(n ¼ 96; 61.1%)
EOA/BSA
 0.76 cm2/m2
(n ¼ 61; 38.9%)
P
value
Preoperative variables
Age (y) 67.8  7.5 65.4  8.3 .06
Female sex 33 (31.7%) 4 (7.5%) <.001
BSA m2 1.88  0.14 1.77  0.15 <.001
NYHA class III 28 (29.3%) 10 (18.9%) .1
Preoperative heart
failure*
7 (7.2%) 4 (6.5%) 1
Surgical variables
Urgent/emergency
operation
10 (9.6%) 4 (7.5%) .3
Bicuspid aortic valve 15 (14.4%) 7 (11.3%) .6
Pump time (min) 87  12 79  19 <.001
Crossclamp time 62  11 57  14 .013
Bioprosthetic valve
19 mm 40 (100%) 0
21 mm 8 (24.3%) 25 (75.7%) <. 001
Mechanical valve
19 mm 22 (82.8%) 5 (17.2%) <.001
21 mm 26 (46.2%) 31 (56.4%) .003
EOAi (cm2/m2) 0.65  0.08 0.8  0.06 <.001
Operative mortality 3 (3.1%) 2 (3.2%) .6
Mean follow-up
time (m)
84.1  32.1 83.1  31.4 .8
Values are expressed as mean standard deviation or number (%). BSA,Body surface
area; NYHA, New York Heart Association; EOAi, indexed effective orifice area. *His-
tory of preoperative hospital admission for heart failure.ardiovascular Surgery c Volume 138, Number 3 633
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features in AVR patients on late clinical status, and (3) identification of other
issues as significant prognostic markers.
Statistical Analysis
Statistical analysis was performed by the SPSS program for Windows
(SPSS, Inc, Chicago, Ill). Continuous data are presented as mean  stan-
dard deviation and categorical data as proportion. Comparison between
continuous variables was done by the Student t test for normally distrib-
uted features. The Mann–Whitney U test was used for variables not nor-
mally distributed. Patient survival and freedom from valve-related
complication were determined by the Kaplan–Meier method. Outcomes
were compared by analysis of the c2 test or the Fisher exact test as
appropriate (categorical variables). Analysis of factors influencing early
and late results was performed calculating the odds ratio (OR) with 95%
confidence intervals (CI). All variables were analyzed in multivariate
logistic regression models to assess the impact of each one on results.
The variables tested in the models were as follows: (1) preoperative—
age, gender, BSA, New York Heart Association functional class, and
ILVM; (2) operative and postoperative—aortic crossclamp time, type
and size of prosthesis implanted, EOAi, PPM, ILVM, MPGs, and ar-
rhythmias. To assess the effect of PPM on variables, we developed a first
model with PPM entered as a dichotomous variable (PPM: EOAi  0.75
cm2/m2 vs no PPM) and then a second model with EOAi entered as
a continuous variable.
RESULTS
Sixty-one percent of patients (96/157) had PPM. Mean
EOAi was 0.69  0.05 in the patients with PPM versus
0.88  0.1 in patients with no PPM (P < .001). Ten
(6.3%) patients had severe PPM (EOAi  0.65 cm2/m2).
Univariate analysis of age, sex, and body mass revealed
that patients with PPM were older, had higher prevalence
of female sex, and larger BSA. Indeed, the only independent
predictor of PPM was unfavorable EOA of the implanted
prosthesis (Table 2). PPM occurred in 89.8% of patients
(62/69) with a 19-mm prosthesis with a significant differ-
ence between mechanical and biological valves (P< .01).
When a 21-mm valve was implanted, PPM occurred in
36.8% of patients (43/88) with a prevalence not statistically
significant in patients with a biological valve (P ¼ .2).
TABLE 2. Types and sizes of prosthetic valves implanted and
reference of effective orifice areas
Valve Size
No. of
patients
EOA*
(cm2) References
Bioprosthetic valve
Medtronic Mosaic 19 mm 40 (25.4%) 1.2 2, 12, 16
21 mm 33 (21.1%) 1.4 6, 12, 15
Mechanical valve
St Jude Medical
Hemodynamic Plus
19 mm 7 (4.5%) 1.3 12, 17
21 mm 19 (12.2%) 1.5 12, 17
St Jude Medical Regent 19 mm 20 (12.7%) 1.5 2, 6
21 mm 26 (16.5%) 2.0 2, 6
Medtronic 19 mm 2 (1.3%) 1.0 12
21 mm 10 (6.3%) 1.3 12
EOA, Effective orifice area. Medtronic, Inc, Minneapolis, Minn; St Jude Medical, Inc,
St Paul, Minn. *EOA derived from values published in the literature.634 The Journal of Thoracic and Cardiovascular SuOverall operative mortality was 3.1% (5 /157). It was
3.1% (3/96) and 3.2% (2/61) for patients with and without
mismatch, respectively (P ¼ .67). Multivariate predictors of
operative mortality were age 70 years or older (OR 1.08,
95% CI, 0.98–1.7), female sex (OR 1.8, 95% CI, 1.2–
2.7), preoperative New York Heart Association class III
(OR 3.2, 95% CI, 2.2–3.9), and history of preoperative hos-
pital admission for heart failure (OR 3.5. 95% CI, 2.4–4.2).
No valve type or expression of valve size was identified as
a risk factor of early mortality (Table 3).
Six patients were lost to follow-up. Redo operations were
necessary in 5 patients with biological and in 2 with mechan-
ical prostheses for malfunctions considered unrelated to
PPM (hemolysis, 1; perivalvular leak, 1; annular fibrosis,
1; endocarditis, 1; and bioprosthesis degenerations, 3).
Late survival at follow-up was 92% (81/88) in the
PPM group versus 92.1% (47/51) in patients without PPM
(P ¼ .5). Three patients (1 with PPM and 2 without) died
suddenly. Other causes of death were embolic stroke in 2,
endocarditis in 2, cancer in 3, and bleeding in 1. PPM failed
to be a significant predictor of related mortality that included
TABLE 3. Mortality
Variables P value Exp CI 95%
Cox survival analysis
Age  70 y <.001 1.1 0.1–1.1
Logistic regression of variables
influencing perioperative death
Age  70 y <.001 3.2 0.98–1.7
Female sex <.001 1.8 1.2–2.7
NYHA class III <.001 3.2 2.2–3.9
Preoperative heart failure* <.001 3.5 2.4–4.2
Variables tested: Age, sex, New York Heart Association class, left ventricular ejection
fraction, mean transprosthetic gradients, effective indexed orifice area less than 0.75,
indexed left ventricular mass, and size and type (mechanical or biological) of valve. CI,
Confidence limits; NYHA,New York Heart Association. *History of preoperative hos-
pital admission for heart failure.
FIGURE 1. Actuarial survival curves, according to Kaplan–Meier
method. Hospital mortality is included. PPM, Prosthesis–patient mismatch.rgery c September 2009
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Preoperative First year Fourth year Final follow-up
PPM No PPM PPM No PPM PPM No PPM PPM No PPM
LVEF (%) 54  8 52  1 58  1 59  4 60  6 61  9 61  3 62  5
MPG 72  12 71  13 18  9 16  5 20  4 19  2 23  8 21  9
ILVM 176  59 178  95 175  88 172  72 160  62 151  44 153  58 148  53
Values are expressed as mean standard deviation. ILVM, Indexed left ventricular mass; LVEF, left ventricular ejection fraction;MPG,mean prosthetic gradient; PPM, prosthesis–
patient mismatch.A
C
Dmechanism of death totally unrelated . The only multivariate
index of late mortality was age 70 years or older (OR 1.12,
95% CI, 0.12–1.11) (Table 3). Actuarial survival curves, ac-
cording to theKaplan–Meiermethod, are reported in Figure 1.
At follow-up, 128 patients (81.5% of the original cohort)
were evaluated between June and November 2007 in the
outpatient department of our institution. Fifty percent of pa-
tients received b-blockers and15% angiotensin-converting
enzyme inhibitors; in 35%, b-blockers and angiotensin-
converting enzyme inhibitor therapy started after surgery.
Echocardiographic evaluations at rest evidenced an im-
provement of LV ejection fraction in both PPM and no
PPM groups without statistically significant differences
(P ¼ .3). One year after surgery, the MPGs were quite low
in both groups without statistically significant differences
(P ¼ .3). These values increased similarly at scheduled
follow-up (Table 4).
Regression of ILVM values was impaired in both groups:
P ¼ .0008 in the PPM series and P ¼ .0002 in the no PPM
series. However, in the PPM group a trend of some postop-
erative reduction was observed even without statistical rele-
vance. Correlation analysis related follow-up time (P¼ .02),
BSA (P ¼ .02), preoperative ILVM values (P ¼ .002), and
late postoperative MPGs (P ¼ .009) with late postoperative
ILVM values. However, multivariate analysis of ILVMThe Journal of Thoracic and Crevealed that only follow-up time (OR 2.5, 95% CI,
1.3–4.7) and preoperative ILVM (OR 2.8, 95% CI,
1.7–3.9) were associated with ILVM greater than 150 g/
m2 in men and 125g/m2 in women at latest follow-up.
Elevated MGP values (35 mm Hg) at rest were reported
in 11.7% of patients (15/128). They occurred in 11.1% of
patients (9/81) in the PPM group versus 6.8% of patients
(3/47) in the no PPM group (P¼ .3). Patients with a mechan-
ical valve had mostly low MPG values as compared with
patients with bioprostheses of the same size (P¼ .03). Echo-
cardiographic evaluation under stress showed that elevated
MPG index was strictly linked to reduced exercise capacity
(OR7.6, 95%CI, 3.4– 9.2;P<.001) (Figure 2).Multivariate
analysis associated high ILVM values (150 g/m2 in
men and 125 g/m2 in women) (OR 3.8, 95% CI, 2.0–7.1;
P < .001), female gender (OR 5.4, 95% CI, 2.8–10.6;
P< .001), and follow-up time of 85 months or more (OR
2.2, 95% CI, 1.2–4.6; P ¼ .006) with high MPGs at rest
and under stress. Basically, in this present series, patients
with abnormal gradients after surgery had LVM regression
at follow-up equivalent to that of patients with low gradients.
This suggests that MPGs did not influence LVM regression.
Stress evaluation showed reduced exercise tolerance in
both PPM and no PPM groups. Patients without PPM
achieved 59%  14% PEC versus 56%  18% in patientsFIGURE 2. Mean pressure gradients (MPGs) at rest and during exercise in patients with versus without prosthesis–patient mismatch (PPM).ardiovascular Surgery c Volume 138, Number 3 635
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than 75% PEC was low in both groups: 23.4% (11/47) in
no PPM versus 19.7 % (16/81) in PPM groups (OR 1.2,
95% CI, 0.6–2.6; P ¼ .6) (Figure 3).
Arrhythmias occurred during exercise test in 33.3 %
of evaluated patients (41/123). During exercise 18 (14.7%)
patients had frequent ventricular ectopic beats, 14 (11.3%)
had bigeminism/trigeminism or couplets, 8 (6.5%) unsus-
tained ventricular tachycardia, and 1 (0.8%) sustained ven-
tricular tachycardia. During recovery from exercise, 12 (9.7
%) subjects had frequent ventricular ectopic beats, 14
(11.4%) had bigeminism/trigeminism or couplets, and 5
(4%) had unsustained ventricular tachycardia. Direct correla-
tion between stress-induced arrhythmias and age greater than
65 years (OR4.5, 95%CI, 2.3–8.6;P<.001),MPGvalues of
50 mm Hg or greater during exercise (OR 2.9, 95% CI,
1.5–5.4; P< .001), high ILVM (OR 5,4, 95% CI, 3.5–8.7;
P< .001), 19-mm bioprosthesis (OR 3.2, 95% CI 1.5–5.9;
P< .001), and BSA of 1.8 m2 or more (OR 4.8, 95% CI,
2.8–7.7;P<.001)were assessed.However,multivariate anal-
ysis of arrhythmias revealed that onlyMPGvalues were inde-
pendently predictive of arrhythmias: values of 50 mm Hg or
more after exercise test had 95% sensitivity and 72% speci-
ficity (area under the curve 0.80) for predicting arrhythmias.
DISCUSSION
PPM occurs when the EOA of an inserted prosthetic valve
is inadequate for the recipient.1,9,12,14 PPM is still a hot issue
and its clinical relevance is not clear. Thus, new information
is needed. PPM can result in persistent LV outflow tract ob-
struction with a high transvalvular gradient that increases
LV work and reduces LVM regression. Surgical results are
controversial. From currently available data, it seems likely
that PPM has an impact on outcome after AVR in some
patients but not in all.25 Many variables that can interfere636 The Journal of Thoracic and Cardiovascular Surwith the occurrence of PPM have been reported. Therefore,
they are more likely registered in patients with a larger body
size, with AS as the predominant lesion (in correlation to
the smaller annular size), and in advanced age (AS by degen-
erative calcification is by far the most prevalent lesion in
older patients undergoing AVR).2
Our retrospective study enlisted a small but homogeneous
population of patients carefully evaluated before and after sur-
gery. All patients were followed up by a number of clinical,
echocardiographic, and functional evaluations at last follow-
up. Our results suggested that PPM, at a threshold of
0.75 cm2/m2, does not result in significant detrimental effects
on overall long-term survival, freedom from heart failure, and
LVM regression in our patients with pure AS and normal
preoperative LV function. These findings are in conflict with
other previous reports in which a larger number of AVRs
were studied. However, these studies included patients with
AS or aortic incompetence or both and patients with poor
LV function.2-5,12,13 Patients with PPM and impaired LV sys-
tolic function at the time of AVR have a greater than twofold
increase in the risk of late death and a fivefold increase in the
cumulative incidence of heart failure by 3 years as compared
with patients with normal LV function and no PPM.25,26 To
avoid anymisleading data, believing thatAShas its own phys-
iology, anatomy, and histology and, accordingly, that PPM
can increase mortality and morbidity in patients with poor
LV function, we selected only patients with pure AS and
goodLVejection fraction.As largely reported, our results con-
firm that PPM incidence is high in the smaller prosthesis sizes.
In our series it occurred in 61.1% of the whole population
(92.5% of patients with a 19-mm prosthesis and 37.7% of
patients with a 21-mm prosthesis). Patients with PPM were
older, female, and had a larger BSA. Bymultivariate analysis,
the only independent predictors of PPM were prosthesis size
and its constructive characteristics.4,7 Operative and lategery c September 2009
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unrelated to PPM were registered. No significant difference
was observed in freedom fromheart-relateddeath or anymajor
adverse cardiac events in patients with PPM as comparedwith
others without PPM. Redo operations for bioprosthetic mal-
function occurred in both groupswithout statistical difference.
This present study confirmed some interesting issues relating
to echocardiographic long-term data. At 8 years’ follow-up,
LVM or the change in LVM indexed for BSA was not signif-
icantly different betweenPPMandnoPPMpatients. Thisfind-
ing may suggest potentially irreversible changes in the
hypertrophied myocites and interstitium as a consequence of
longstanding disease with impaired ventricular geometry
and abnormal relaxation.27-29 TheMPGsat restwere generally
low and clinically insignificant regardless of PPMoccurrence.
To satisfy the third end point, we investigated the impact
of PPM on exercise capacity with regard to gender, age, and
body weight30: inasmuch as patients with heart valve disease
have a reduced exercise capability compared with the
healthy population,31 it is not surprising that only 25.4%
of our patients achieved PEC of 75% regardless of the oc-
currence of PPM. Abnormal increment of the MPG (up to
50 mm Hg) values occurred in a large number of patients.
Less exercise tolerance was registered in patients with
higher LVMI and increased MPGs at stress. These results
were not surprising considering that high transprosthetic
gradients limit the increase of cardiac output during exercise
similar to what happens in native AS and limit the capability
of cardiac function to match the increasing metabolic de-
mand during exercise.
However, the major finding of our study is the evidence of
exercise-induced arrhythmias in one third of our patients.
This incidence rises to 62.4% in the patients with significant
increment of the MPG values under stress, even in patients
with normal or moderate gradients at rest. In all patients,
the increased duration of exercise was associated with
more adverse events. Probably, the persistently elevated
LVM, the impaired ventricular geometry, and the abnormal
coronary flow reserve after AVR may predispose to the ar-
rhythmias in patients with and without mismatch.31-34 This
study confirms that, beyond occurrence of PPM, patients
who underwent AVR with a small prostheses for pure AS
have less exercise capacity and adds the important issue
that they have significantly increased risk of arrhythmias.
Intuitively, arrhythmias occurring during exercise should
have an adverse impact on clinical outcome, but we failed
to confirm this issue in our series. Our data, which we first
describe, are very difficult to interpret. To our knowledge,
studies that address the clinical long-term follow-up or the
LV hypertrophy evaluations after AVR usually did not
include details on these findings; equally, other studies of
the impact of PPM on exercise capacity did not fully inves-
tigate modifications of prosthetic gradients under stress and
occurrence of arrhythmias, especially in patients withThe Journal of Thoracic and Ca nearly normal gradient at rest. A possible explanation for
these apparently conflicting results might be the protective
effect of therapy with b-blockers and/or angiotensin-con-
verting enzyme inhibitors received by 95% of our patients
and withdrawn 5 days before exercise tests.
In conclusion, our results on a small population of patients
cannot confirm with absolute statistical power whether PPM
can or cannot be an independent predictor of early and late
mortality; indeed, we believe that meaningful survival data
can be obtained only from studies with a very large number
of patients. However, our study confirms that PPM impairs
LVM regression, but mainly it first shows that high LVM
and increased transprosthetic gradient during exercise are
strictly linked and have high sensitivity and specificity for
predicting risk of arrhythmias. Postoperative extensive use
of b-blockers and/or angiotensin-converting enzyme inhibi-
tors may be useful in preventing these complications and
improving early and late survival. Our study adds some
new statement in the complex challenge of PPM, but further
investigations will be necessary to confirm our preliminary
observations in a larger sample of patients. Nevertheless,
in our opinion, PPM may become a serious problem only
in a particular risk population that needs a specific surgical
strategy to minimize the risk of PPM.
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